Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
Dosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24Company init...
United States Jesse Shefferman Klinische Einheit Justine Omalley Exchange Commission Protara Therapeutics Inc
Source: businessinsider.com